Skip to main content
TipRanks
Go Ultimate75% OFF
EIT Pharma logo

EIT Pharma: Valuation, Funding & Investors

A biotechnology company focused on developing therapies for infectious diseases. Its pipeline includes late-stage treatments such as lonafarnib for chronic hepatitis D.

Leadership & Board

Latest Estimated Valuation

Total Amount Raised
$35M
Total Funding Rounds
1
Latest Funding Amount
$35M
Latest Funding Round
Series A

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Aug 31, 2026Series A$35.00M―

Investors

Investor NameFunding Round
Propel Bio PartnersSeries A
Good VenturesSeries A
ArrowtownSeries A

Similar Companies

A snapshot of private companies similar to EIT Pharma, helping you discover and navigate related company profiles.

Related News and Analysis